Greenwich LifeSciences Receives Nasdaq Notification Regarding 10-K Filing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 22 2026
0mins
Should l Buy GLSI?
Source: seekingalpha
- Nasdaq Compliance Notification: Greenwich LifeSciences received a notification from Nasdaq indicating non-compliance due to the failure to file its 10-K report for the fiscal year ending December 31, 2025, although this notice does not have an immediate impact on the listing or trading of its stock.
- Stock Trading Status: The company's common stock continues to trade on the Nasdaq Capital Market under the symbol 'GLSI', indicating that despite compliance issues, the liquidity of its shares remains unaffected in the market.
- Future Plans: The company intends to file its 10-K for the fiscal year 2025 as soon as possible, demonstrating a proactive approach to resolving compliance issues and aiming to restore full compliance with Nasdaq regulations.
- Investor Attention: Despite facing compliance challenges, recent open-label data and patent claims from Greenwich LifeSciences continue to attract investor interest, which may influence its future market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GLSI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GLSI
Wall Street analysts forecast GLSI stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 22.860
Low
45.00
Averages
47.50
High
50.00
Current: 22.860
Low
45.00
Averages
47.50
High
50.00
About GLSI
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9-amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2) /neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. It has commenced a Phase III clinical trial, Flamingo-01, an immunotherapy to prevent breast cancer recurrences. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Greenwich LifeSciences Receives Nasdaq Notification Regarding 10-K Filing
- Nasdaq Compliance Notification: Greenwich LifeSciences received a notification from Nasdaq indicating non-compliance due to the failure to file its 10-K report for the fiscal year ending December 31, 2025, although this notice does not have an immediate impact on the listing or trading of its stock.
- Stock Trading Status: The company's common stock continues to trade on the Nasdaq Capital Market under the symbol 'GLSI', indicating that despite compliance issues, the liquidity of its shares remains unaffected in the market.
- Future Plans: The company intends to file its 10-K for the fiscal year 2025 as soon as possible, demonstrating a proactive approach to resolving compliance issues and aiming to restore full compliance with Nasdaq regulations.
- Investor Attention: Despite facing compliance challenges, recent open-label data and patent claims from Greenwich LifeSciences continue to attract investor interest, which may influence its future market performance.
See More
Greenwich LifeSciences Expands Vaccine Trial to Broader Patient Population
- Trial Expansion Plans: CEO Snehal Patel announced that the FDA has reviewed plans to expand the trial to include all patient types, with over 1,300 patients enrolled, indicating a significant market opportunity for the breast cancer vaccine.
- Significant Immune Response Increase: Data presented at the 2026 AACR Annual Meeting revealed that the vaccine candidate GLSI-100 showed nearly a 4-fold increase in immune response in non-HLA-A*02 patients, with some patients improving by 2 to 8 times, demonstrating its broader applicability.
- Clinical Trial Results: In the Phase III FLAMINGO-01 trial, delayed-type hypersensitivity (DTH) responses in the specific HLA-A*02 patient cohort increased fourfold from month 4 to 6 of treatment, indicating significant immune activation by the vaccine.
- Positive Market Reaction: Shares of Greenwich LifeSciences rose over 2% in premarket trading on Monday, and the stock has increased by over 28% year-to-date, reflecting bullish sentiment among retail investors regarding the company's prospects.
See More
Greenwich LifeSciences Presents Significant Data from GLSI-100 Phase III Trial
- Significant Immune Response: In the FLAMINGO-01 trial, 247 non-HLA-A*02 patients receiving GLSI-100 showed an increase in immune responses from 5.2% at baseline to 20.4% at four or six months, with statistical significance at p < 0.001, indicating the drug's effectiveness in activating the immune system against recurrent breast cancer.
- Reduction in Recurrence Rates: Preliminary analyses suggest a 70-80% reduction in recurrence rates after the primary immunization series in non-HLA-A*02 patients, consistent with earlier Phase IIb results, further validating the therapeutic potential of GLSI-100.
- Trial Design and Patient Recruitment: The FLAMINGO-01 trial has screened over 1,300 patients across U.S. and European sites, reflecting strong patient interest, with a design that includes six initial GLSI-100 injections over six months followed by booster doses every six months, aiming for long-term protection.
- Market Performance and Stock Dynamics: GLSI's stock has traded between $7.78 and $34.10 over the past year, closing at $27.74, up 2.36% from the previous trading day, indicating a positive market reaction to its clinical data.
See More
Greenwich LifeSciences Updates Financing Strategy Amid Phase III Trial Progress
- Financing Strategy Update: Greenwich LifeSciences has successfully utilized its ATM financing vehicle to raise funds exceeding its cash burn rate in Q1 2026, resulting in a cash balance of approximately $10.5 million, indicating financial stability during its clinical trial phase.
- Clinical Trial Progress: In the FLAMINGO-01 trial, over 1,000 patients have been screened, with all 250 patients in the non-HLA-A*02 arm fully enrolled, representing five times the number of treated patients compared to the Phase IIb trial, highlighting the company's potential in breast cancer recurrence prevention.
- Significant Recurrence Rate Reduction: Preliminary data indicates a 70-80% reduction in recurrence rates in the non-HLA-A*02 arm after completing the Primary Immunization Series, aligning with the 80% reduction observed in the Phase IIb trial, showcasing the efficacy of GLSI-100.
- Global Clinical Network Expansion: The FLAMINGO-01 trial plans to open up to 150 clinical trial sites globally, with approximately 500 HLA-A*02 patients expected to participate, aiming to enhance the reliability of clinical outcomes and strengthen market competitiveness through extensive data collection.
See More
Greenwich LifeSciences Updates Patent Claims for GLSI-100
- Patent Claims Expansion: Based on statistically significant immune response and recurrence rate data from the FLAMINGO-01 trial, Greenwich LifeSciences has filed new patent claims asserting that GLSI-100 clinically benefits non-HLA-A*02 patients, potentially doubling the market to 88,000 new patients annually, significantly enhancing the company's revenue prospects in the breast cancer immunotherapy market.
- Clinical Trial Progress: The FLAMINGO-01 trial has screened over 1,000 patients, with the 250-patient non-HLA-A*02 arm fully enrolled, all receiving GLSI-100, demonstrating an 80% reduction in recurrence rates similar to Phase IIb trial results, indicating the therapy's efficacy and safety.
- Market Potential: CEO Snehal Patel highlighted that the new patent claims support a market potential of up to $10 billion annually for GLSI-100, with the company already enrolling both HLA-A02 and non-HLA-A02 patients in FLAMINGO-01 to leverage increased statistical power from combined analyses.
- Future Outlook: If the patent claims are granted, they could provide patent protection through 2045, further solidifying the company's competitive position in breast cancer immunotherapy while laying the groundwork for future clinical research and market expansion.
See More
Greenwich LifeSciences Reports Promising Phase 3 Trial Data for GLSI-100
- Clinical Trial Results: Greenwich LifeSciences' Phase 3 FLAMINGO-01 trial shows that breast cancer recurrence rates in patients receiving GLSI-100 dropped to less than 1% per year, an 83% reduction compared to the historical 4% rate, marking a significant advancement for the immunotherapy candidate.
- Patient Data Analysis: The open-label arm of the trial includes 250 patients without the HLA-A*02 genetic marker, all of whom received GLSI-100 after standard treatment with Kadcyla; after an average follow-up of 1.2 years, the recurrence rate was just 0.7%, demonstrating substantial clinical efficacy.
- Future Outlook: Although this arm lacks a placebo group, the company assesses efficacy through historical comparisons and plans to update data as more patient years accumulate, with future results expected to be presented at upcoming conferences to further validate the therapy's effectiveness.
- Market Reaction: GLSI's stock has traded between $7.78 and $34.10 over the past year, closing at $28.13 on Monday with a 5.20% increase, and rising to $33.58 in pre-market trading, up 20%, reflecting positive market expectations for the therapy.
See More
Greenwich LifeSciences Receives Nasdaq Notification Regarding 10-K Filing
- Nasdaq Compliance Notification: Greenwich LifeSciences received a notification from Nasdaq indicating non-compliance due to the failure to file its 10-K report for the fiscal year ending December 31, 2025, although this notice does not have an immediate impact on the listing or trading of its stock.
- Stock Trading Status: The company's common stock continues to trade on the Nasdaq Capital Market under the symbol 'GLSI', indicating that despite compliance issues, the liquidity of its shares remains unaffected in the market.
- Future Plans: The company intends to file its 10-K for the fiscal year 2025 as soon as possible, demonstrating a proactive approach to resolving compliance issues and aiming to restore full compliance with Nasdaq regulations.
- Investor Attention: Despite facing compliance challenges, recent open-label data and patent claims from Greenwich LifeSciences continue to attract investor interest, which may influence its future market performance.
See More
Greenwich LifeSciences Expands Vaccine Trial to Broader Patient Population
- Trial Expansion Plans: CEO Snehal Patel announced that the FDA has reviewed plans to expand the trial to include all patient types, with over 1,300 patients enrolled, indicating a significant market opportunity for the breast cancer vaccine.
- Significant Immune Response Increase: Data presented at the 2026 AACR Annual Meeting revealed that the vaccine candidate GLSI-100 showed nearly a 4-fold increase in immune response in non-HLA-A*02 patients, with some patients improving by 2 to 8 times, demonstrating its broader applicability.
- Clinical Trial Results: In the Phase III FLAMINGO-01 trial, delayed-type hypersensitivity (DTH) responses in the specific HLA-A*02 patient cohort increased fourfold from month 4 to 6 of treatment, indicating significant immune activation by the vaccine.
- Positive Market Reaction: Shares of Greenwich LifeSciences rose over 2% in premarket trading on Monday, and the stock has increased by over 28% year-to-date, reflecting bullish sentiment among retail investors regarding the company's prospects.
See More
Greenwich LifeSciences Presents Significant Data from GLSI-100 Phase III Trial
- Significant Immune Response: In the FLAMINGO-01 trial, 247 non-HLA-A*02 patients receiving GLSI-100 showed an increase in immune responses from 5.2% at baseline to 20.4% at four or six months, with statistical significance at p < 0.001, indicating the drug's effectiveness in activating the immune system against recurrent breast cancer.
- Reduction in Recurrence Rates: Preliminary analyses suggest a 70-80% reduction in recurrence rates after the primary immunization series in non-HLA-A*02 patients, consistent with earlier Phase IIb results, further validating the therapeutic potential of GLSI-100.
- Trial Design and Patient Recruitment: The FLAMINGO-01 trial has screened over 1,300 patients across U.S. and European sites, reflecting strong patient interest, with a design that includes six initial GLSI-100 injections over six months followed by booster doses every six months, aiming for long-term protection.
- Market Performance and Stock Dynamics: GLSI's stock has traded between $7.78 and $34.10 over the past year, closing at $27.74, up 2.36% from the previous trading day, indicating a positive market reaction to its clinical data.
See More
Greenwich LifeSciences Updates Financing Strategy Amid Phase III Trial Progress
- Financing Strategy Update: Greenwich LifeSciences has successfully utilized its ATM financing vehicle to raise funds exceeding its cash burn rate in Q1 2026, resulting in a cash balance of approximately $10.5 million, indicating financial stability during its clinical trial phase.
- Clinical Trial Progress: In the FLAMINGO-01 trial, over 1,000 patients have been screened, with all 250 patients in the non-HLA-A*02 arm fully enrolled, representing five times the number of treated patients compared to the Phase IIb trial, highlighting the company's potential in breast cancer recurrence prevention.
- Significant Recurrence Rate Reduction: Preliminary data indicates a 70-80% reduction in recurrence rates in the non-HLA-A*02 arm after completing the Primary Immunization Series, aligning with the 80% reduction observed in the Phase IIb trial, showcasing the efficacy of GLSI-100.
- Global Clinical Network Expansion: The FLAMINGO-01 trial plans to open up to 150 clinical trial sites globally, with approximately 500 HLA-A*02 patients expected to participate, aiming to enhance the reliability of clinical outcomes and strengthen market competitiveness through extensive data collection.
See More
Greenwich LifeSciences Updates Patent Claims for GLSI-100
- Patent Claims Expansion: Based on statistically significant immune response and recurrence rate data from the FLAMINGO-01 trial, Greenwich LifeSciences has filed new patent claims asserting that GLSI-100 clinically benefits non-HLA-A*02 patients, potentially doubling the market to 88,000 new patients annually, significantly enhancing the company's revenue prospects in the breast cancer immunotherapy market.
- Clinical Trial Progress: The FLAMINGO-01 trial has screened over 1,000 patients, with the 250-patient non-HLA-A*02 arm fully enrolled, all receiving GLSI-100, demonstrating an 80% reduction in recurrence rates similar to Phase IIb trial results, indicating the therapy's efficacy and safety.
- Market Potential: CEO Snehal Patel highlighted that the new patent claims support a market potential of up to $10 billion annually for GLSI-100, with the company already enrolling both HLA-A02 and non-HLA-A02 patients in FLAMINGO-01 to leverage increased statistical power from combined analyses.
- Future Outlook: If the patent claims are granted, they could provide patent protection through 2045, further solidifying the company's competitive position in breast cancer immunotherapy while laying the groundwork for future clinical research and market expansion.
See More
Greenwich LifeSciences Reports Promising Phase 3 Trial Data for GLSI-100
- Clinical Trial Results: Greenwich LifeSciences' Phase 3 FLAMINGO-01 trial shows that breast cancer recurrence rates in patients receiving GLSI-100 dropped to less than 1% per year, an 83% reduction compared to the historical 4% rate, marking a significant advancement for the immunotherapy candidate.
- Patient Data Analysis: The open-label arm of the trial includes 250 patients without the HLA-A*02 genetic marker, all of whom received GLSI-100 after standard treatment with Kadcyla; after an average follow-up of 1.2 years, the recurrence rate was just 0.7%, demonstrating substantial clinical efficacy.
- Future Outlook: Although this arm lacks a placebo group, the company assesses efficacy through historical comparisons and plans to update data as more patient years accumulate, with future results expected to be presented at upcoming conferences to further validate the therapy's effectiveness.
- Market Reaction: GLSI's stock has traded between $7.78 and $34.10 over the past year, closing at $28.13 on Monday with a 5.20% increase, and rising to $33.58 in pre-market trading, up 20%, reflecting positive market expectations for the therapy.
See More
